Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...
BioSpace2d
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
Healio1d
‘Pivotal moment’: Uplizna becomes first FDA-approved treatment for IgG4-related disease
The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...
The American Journal of Managed Care2d
Inebilizumab FDA Approved as First Treatment for IgG4-RD
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4 ...
Healio2d
Rilzabrutinib granted orphan drug designation for IgG4-related disease
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Pharmabiz1d
US FDA approves Amgen’s Uplizna to treat IgG4-related disease
US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...
Medscape1d
FDA Approves First and Only Therapy for IgG4-RD
Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
pharmaphorum2d
Uplizna is first drug FDA-cleared for rare disease IgG4-RD
Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...
Morningstar3d
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...